Lexicon Pharmaceuticals Inc.’s (LXRX) New Drug Application for Telotristat etiprate, an oral drug for the treatment of carcinoid syndrome has been granted priority review by the FDA – with a decision scheduled for November 30, 2016.
Forex – financial instrument.Forex news
Lexicon Pharmaceuticals Inc.’s (LXRX) New Drug Application for Telotristat etiprate, an oral drug for the treatment of carcinoid syndrome has been granted priority review by the FDA – with a decision scheduled for November 30, 2016.